People · Operator
Named in public records as an officer, director or promoter · active 2012–2026 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Metagenomi Technologies, LLC | — | Biotechnology | Series D+ | $345.1M | $1.7B | 2021 |
| Eliem Therapeutics, Inc. | — | Pharmaceuticals | Series D+ | $253.2M | $1.3B | 2019 |
| Triana Biomedicines, Inc. | — | Pharmaceuticals | Series D+ | $178.6M | $852.1M | 2020 |
| Imbria Pharmaceuticals, Inc. | — | Biotechnology | Series C | $140.2M | $405.5M | 2025 |
| Arvinas, Inc. | — | Biotechnology | Series C | $129.1M | $1.3B | 2015 |
| Solstice Oncology, Inc. | — | Biotechnology | Series D+ | $121.3M | $773.7M | 2026 |
| Cytek BioSciences, Inc. | — | Biotechnology | Series D+ | $120.0M | $4.5B | 2020 |
| Aerovate Therapeutics, Inc. | — | Pharmaceuticals | Series C | $78.3M | $2.6B | 2019 |
| Lusaris Therapeutics, Inc. | — | Pharmaceuticals | Series C | $60.2M | $954.8M | 2022 |
| Superluminal Medicines, Inc. | — | Biotechnology | Series B | $50.7M | $22.0M | 2023 |
| Synthorx, Inc. | — | Biotechnology | Series B | $34.7M | $1.1B | 2016 |
| Athenen Therapeutics, Inc. | — | Pharmaceuticals | Series A | $12.0M | $371.7M | 2019 |
| Slate Medicines, Inc. | — | Pharmaceuticals | Series A | $10.0M | $24.8M | 2026 |
| Arcuate Therapeutics, Inc. | — | Pharmaceuticals | Series A | $5.0M | $154.9M | 2019 |
| Pahr Therapeutics, Inc. | — | Biotechnology | Series A | $4.7M | $17.8M | 2025 |
| CleanBreak, Inc. | — | Biotechnology | Seed | $2.0M | $88.8M | 2017 |
| Immunetics, Inc. | — | Biotechnology | Pre-Seed | $1.5M | $46.1M | 2012 |
ANDREW LEVIN at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside ANDREW LEVIN on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Joshua Resnick | 4 | 12 |
| James Schneider | 3 | 5 |
| Neil Buckley | 3 | 3 |
| Adam Rosenberg | 2 | 6 |
| Liam Ratcliffe | 2 | 4 |
| CATHERINE RIESEN | 2 | 2 |
| Aaron Bergener | 2 | 2 |
| Ken Horne | 2 | 2 |
| Sarah Reed | 2 | 2 |
| Peter Thompson | 1 | 16 |
| Shelley Chu | 1 | 10 |
| Kush Parmar | 1 | 10 |
| Jack Ball | 1 | 10 |
| Risa Stack | 1 | 9 |
| Tim Shannon | 1 | 9 |
| Dylan Morris | 1 | 8 |
| Stephen Squinto | 1 | 8 |
| Christopher O'Donnell | 1 | 8 |
| Tighe Reardon | 1 | 7 |
| Jay Lichter | 1 | 7 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.